Guanling Chen1, Zhaoze Guo1, Minfeng Liu, Guangyu Yao, Jianyu Dong, Jingyun Guo, Changsheng Ye
Oncology Research, Vol.25, No.9, pp. 1567-1578, 2017, DOI:10.3727/096504017X14897173032733
Abstract Capecitabine has consistently demonstrated high efficacy and acceptable tolerability in salvage chemotherapy
for advanced breast cancer. However, there remains no consensus on its role in adjuvant chemotherapy for early
breast cancer (EBC). To estimate the value of capecitabine-based combination adjuvant treatment in EBC,
eight randomized controlled trials with 14,072 participants were analyzed. The efficacy and safety outcomes
included disease-free survival (DFS), overall survival (OS), relapse, breast cancer-specific survival (BCSS),
and grades 3–5 adverse events. Capecitabine-based combination adjuvant chemotherapy demonstrated a 16%
increase in BCSS (HR = 0.84, 95% CI = 0.71–0.98, p = 0.03) in the… More >
Login
Register
